Triclabendazole for the treatment of fascioliasis and paragonimiasis.
about
Helminth infections: the great neglected tropical diseasesFood-borne trematodiasesNorth American paragonimiasis (Caused by Paragonimus kellicotti) in the context of global paragonimiasisRepurposing drugs for the treatment and control of helminth infectionsAn Outbreak of Human Fascioliasis gigantica in Southwest ChinaA prospective view of animal and human FasciolosisDevelopment of functional genomic tools in trematodes: RNA interference and luciferase reporter gene activity in Fasciola hepaticaTribendimidine and albendazole for treating soil-transmitted helminths, Strongyloides stercoralis and Taenia spp.: open-label randomized trialEfficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trialsThe small molecule triclabendazole decreases the intracellular level of cyclic AMP and increases resistance to stress in Saccharomyces cerevisiaeTriclabendazole sulfoxide causes stage-dependent embryolethality in zebrafish and mouse in vitroTreatment Failure after Multiple Courses of Triclabendazole among Patients with Fascioliasis in Cusco, Peru: A Case SeriesParagonimiasis acquired in the United States: native and nonnative speciesWater-related parasitic diseases in ChinaParasitic pneumonia and lung involvementFasciola hepatica and Schistosoma mansoni: identification of common proteins by comparative proteomic analysis.A case of probable mixed-infection with Clonorchis sinensis and Fasciola sp.: CT and parasitological findings.In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78Trematocidal activity of praziquantel and artemisinin derivatives: in vitro and in vivo investigations with adult Echinostoma caproni.Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano.A Case of Fascioliasis Treated Successfully Without Sequelae in a Japanese Expatriate Living in JakartaIn vitro tegumental alterations on adult Fasciola gigantica caused by mefloquine.Unusual case of a lung abscessPraziquantel treatment in trematode and cestode infections: an updatePharmacokinetics of the fasciocidal drug candidates MT04 and OZ78 in uninfected rats and in vitro pharmacodynamic studies.Triclabendazole progress report, 2005-2009: an advancement of learning?In vitro and in vivo trematode models for chemotherapeutic studies.Complete mitochondrial genomes of the 'intermediate form' of Fasciola and Fasciola gigantica, and their comparison with F. hepatica.Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control.Neglected tropical diseases: survey and geometry of randomised evidence.Advances in the discovery and development of trematocidal drugs.North American paragonimiasis: epidemiology and diagnostic strategies.Preventive chemotherapy in human helminthiasis: theoretical and operational aspects.Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children.Effect of a novel benzimidazole derivative in experimental Schistosoma mansoni infection.A mucin-like peptide from Fasciola hepatica induces parasite-specific Th1-type cell immunity.Efficacy of a single oral dose of oxfendazole against Fasciola hepatica in naturally infected sheepIn vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis.The anti-fasciolasis properties of silver nanoparticles produced by Trichoderma harzianum and their improvement of the anti-fasciolasis drug triclabendazole.Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands.
P2860
Q24648324-C28174F9-6C2C-4512-AABA-223D74B71D6BQ24650873-5B646485-B9E2-4660-8998-9C27C7636B6FQ24650895-C4ABCBE1-827C-4C0F-9ED4-95CF6BB35772Q26823355-4079EEF9-A553-4319-8A9B-33C460EC6F19Q27309267-6C5ED4D2-1BC7-4820-9DD2-0AEAD65D7C2DQ28067643-02F35FBC-961D-45B1-8647-2A663F63EB60Q28473071-516DBA6C-3FEE-4BED-BD1F-60651EE0E7A5Q28473776-53F62DB5-0484-47CD-A144-06FFCE22B6E3Q28476800-BAE0553D-7899-4C0E-945B-232B92521224Q28487770-D5297995-F58B-402A-BAB9-0C524C7C6A80Q28544746-0581AC99-3D20-45A8-9FD4-59068D701C4BQ28552800-F1D8487E-1D48-46B3-BB89-FCFF9E1C45D6Q28675838-7F8381A2-DAB7-4D2C-A917-262405B5FFF8Q28678670-F6C21435-F56C-4911-A3E8-4467FD978E60Q33796627-091D8EA9-753C-4DE2-BE83-711119C16B3BQ33877592-3EABB947-D027-4CED-B2D8-C832281FBD6DQ33942744-F5FDD799-60B2-402C-902F-1221D597BD03Q34290075-CA1F9C20-5CE8-45BD-AF4B-F5BEAC0E8B63Q34352275-8618ED17-0554-4EC8-A0B5-2B5BAB3CD326Q34374888-0EACCCE3-EB60-4323-8E3B-765E4A1B431EQ35944943-A32199CE-877B-4E44-B1BB-08F2023F6290Q36750810-216C3F89-EAE9-4CE0-B42B-0EB0F77142CAQ36818113-B7A0194D-56AF-4B7B-B3C7-818A3ADA7942Q37192109-D9BAB0EB-29A9-4278-B361-5000E964EC53Q37390557-66FC9749-BBDB-43E3-A242-0557A11647C6Q37444251-B1B048E3-A4CD-425E-9FAF-D5C368652181Q37644571-0031AE07-7AFD-4390-BFCC-DB4AF0E6D189Q37720209-5EB71F4D-4A91-402D-B22D-BADBFD7359AFQ37846890-3E0D0BF6-1D66-4BE5-BD38-701CC98F8325Q38054293-4F6E4458-E2B2-4A8A-97AE-DBC2FD1D587DQ38089167-2FE86187-C8C5-42D6-925F-A0455BBAA59EQ38401810-153E9ACB-A20D-4337-B679-502B3F9893B9Q39014924-C2F21D43-934B-43F1-9690-CFF56898004AQ39201216-27F6D7BE-0916-48DE-A5FB-324E1467F468Q39338872-2E12DAF7-618E-4F3F-98C9-98241FCF0205Q40242084-7F8F18F8-AC33-401B-8C27-63C49F768806Q41436763-99F4CB3E-1AB2-401D-9CC1-E639E34B6A7BQ42272747-7B3A1CF2-7ECA-4566-B9DF-48CB73024FCAQ42836061-270D00BA-D116-4E2A-846C-17323B825FA7Q43180493-4E9FEF36-6151-4903-A700-AB04B4C00DF0
P2860
Triclabendazole for the treatment of fascioliasis and paragonimiasis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Triclabendazole for the treatment of fascioliasis and paragonimiasis.
@ast
Triclabendazole for the treatment of fascioliasis and paragonimiasis.
@en
type
label
Triclabendazole for the treatment of fascioliasis and paragonimiasis.
@ast
Triclabendazole for the treatment of fascioliasis and paragonimiasis.
@en
prefLabel
Triclabendazole for the treatment of fascioliasis and paragonimiasis.
@ast
Triclabendazole for the treatment of fascioliasis and paragonimiasis.
@en
P2860
P1476
Triclabendazole for the treatment of fascioliasis and paragonimiasis.
@en
P2093
Dirk Engels
Gottfried Büscher
P2860
P304
P356
10.1517/13543784.14.12.1513
P407
P577
2005-12-01T00:00:00Z